Lee Kevin P, Vangipuram Ramya K, Klimas Natasha K, Sanyal Soma, Koshelev Misha V
McGovern Medical School, Houston, TX.
Dermatol Online J. 2019 Oct 15;25(10):13030/qt6q51c0p9.
Hydroxyurea is a chemotherapeutic agent that is used in the treatment of various hematological diseases including chronic myelogenous leukemia, polycythemia vera, and sickle cell anemia. Hydroxyurea is also used to treat psoriasis. Drug-induced hyperpigmentation is a known cutaneous side effect of hydroxyurea along with xerosis, dermal ulcers, and dermatomyositis-like eruptions. Hyperpigmentation has been observed in the oral mucosa, nails, and in a generalized or a diffuse pattern. The mechanism of hyperpigmentation related to hydroxyurea is believed to be correlated with increased melanin. Classically, clinical types of diffuse hyperpigmentation owing to iron deposition in the dermis have been associated with minocycline and not with hydroxyurea. We report a novel case in which hydroxyurea hyperpigmentation is associated with iron deposition.
羟基脲是一种化疗药物，用于治疗各种血液系统疾病，包括慢性粒细胞白血病、真性红细胞增多症和镰状细胞贫血。羟基脲也用于治疗银屑病。药物性色素沉着是羟基脲已知的皮肤副作用，此外还有皮肤干燥、皮肤溃疡和皮肌炎样皮疹。色素沉着已在口腔黏膜、指甲以及全身性或弥漫性分布中观察到。与羟基脲相关的色素沉着机制被认为与黑色素增加有关。传统上，由于真皮中铁沉积导致的弥漫性色素沉着的临床类型与米诺环素有关，而与羟基脲无关。我们报告了一例新病例，其中羟基脲色素沉着与铁沉积有关。
